Myeloma 2022: day two highlights
Episode 153 of the VJHemOnc Podcast podcast, hosted by VJHemOnc, titled "Myeloma 2022: day two highlights" was published on September 2, 2022 and runs 11 minutes.
September 2, 2022 ·11m · VJHemOnc Podcast
Summary
There were several fascinating sessions and discussions at the Myeloma 2022 meeting that took place in Scottsdale, AZ. Topics that were covered include: the role of genomics in the age of immuno-oncology, novel targets and agents, T-cell engagers, and resistance to immunotherapies. In this podcast, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York, NY, Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Leif Bergsagel, Mayo Clinic, Phoenix, AZ, and Keith Stewart, MB, ChB, Princess Margaret Cancer Centre, Toronto, Canada, share their highlights from day two of the Myeloma 2022 meeting. The experts cover several topics, including the biology behind BCL2 inhibitors, T-cell exhaustion and its role in resistance to immunotherapies, and more.
Episode Description
There were several fascinating sessions and discussions at the Myeloma 2022 meeting that took place in Scottsdale, AZ. Topics that were covered include: the role of genomics in the age of immuno-oncology, novel targets and agents, T-cell engagers, and resistance to immunotherapies.
In this podcast, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York, NY, Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Leif Bergsagel, Mayo Clinic, Phoenix, AZ, and Keith Stewart, MB, ChB, Princess Margaret Cancer Centre, Toronto, Canada, share their highlights from day two of the Myeloma 2022 meeting. The experts cover several topics, including the biology behind BCL2 inhibitors, T-cell exhaustion and its role in resistance to immunotherapies, and more.
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.